Categories
Disease Modifying Anti-rheumatic Drugs,DMARDs Mycophenolate Pharmacology Physiotherapy

Mycophenolate and Ganciclovir

In this article we will discuss Mycophenolate and Ganciclovir

In this article, we will discuss Mycophenolate and Ganciclovir. So, let’s get started.

Mycophenolate and Ganciclovir

Following single-dose administration to 12 stable renal transplant patients, no
pharmacokinetic interaction was observed between mycophenolate mofetil (1.5 g) and
intravenous ganciclovir (5 mg/kg). Mean (±SD) ganciclovir AUC and Cmax (n=10) were 54.3 (±19.0) μg•h/mL and 11.5 (±1.8) μg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (±17.0) μg•h/mL and 10.6 (±2.0) μg/mL, respectively, after administration of intravenous ganciclovir alone. The mean (±SD) AUC and Cmax of MPA (n=12) after coadministration were 80.9 (±21.6) μg•h/mL and 27.8 (±13.9) μg/mL, respectively, compared to values of 80.3 (±16.4) μg•h/mL and 30.9 (±11.2) μg/mL,
respectively, after administration of mycophenolate mofetil alone. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are
ganciclovir concentrations, the two drugs will compete for tubular secretion and thus
further increases in concentrations of both drugs may occur. In patients with renal
impairment in which MMF and ganciclovir or its prodrug (eg, valganciclovir) are
coadministered, patients should be monitored carefully.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.